Log In
BCIQ
Print this Print this
 

DCR-PH1

  Manage Alerts
Collapse Summary General Information
Company Dicerna Pharmaceuticals Inc.
DescriptionDicer substrate short interfering RNA (siRNA) targeting mRNA carrying the hydroxyacid oxidase 1 (HAO1) gene
Molecular Target Hydroxyacid oxidase 1 (HAO1) mRNA
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPhase I
Standard IndicationHyperoxaluria
Indication DetailsTreat primary hyperoxaluria type 1
Regulatory Designation U.S. - Orphan Drug (Treat primary hyperoxaluria type 1);
EU - Orphan Drug (Treat primary hyperoxaluria type 1)
PartnerArbutus Biopharma Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$24.5M

$2.5M

$22.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/17/2014

$24.5M

$2.5M

$22.0M

Get a free BioCentury trial today